Original Research

Page 12

Posts about this type

PCC
Cholesterol, Obesity, and Metabolic Syndrome in Epileptic Patients
JCP
Transdermal HP-3070 for Hostility in Schizophrenia
JCP
Suicide Risk in a National VA Sample
JCP
Long-term Outcomes of Early Use of LAIs in Schizophrenia
PCC
Sleep in Older Adults During the COVID-19 Pandemic
JCP
Efficacy and Safety of AXS-05 (Dextromethorphan-Bupropion) in MDD
PCC
Attachment Styles and Mental Health in Adolescents
JCP
Clozapine Use in Singapore and Hong Kong
JCP
Youth Aware of Mental Health (YAM) Intervention
JCP
Eating Disorders in Youth With Bipolar Disorder
JCP
Antipsychotic Efficacy of KarXT (Xanomeline−Trospium)
Original Research

image/svg+xml art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos Open Access logo, converted into svg, designed by PLoS. This version with transparent background. http://commons.wikimedia.org/wiki/File:Open_Access_logo_PLoS_white.svg art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos http://www.plos.org/ May 11, 2022

This post hoc analysis of phase 2 data evaluated rates and time course of response with the new combination oral agent KarXT (xanomeline−trospium) in the treatment of schizophrenia.
PCC
Social and Emotional Health of College Students and COVID-19
JCP
Daily Dose Effects of Risperidone on Metabolic Parameters
PCC
Resilience, Coping, Distress, and COVID-19
PCC
Psychological Morbidity Among COVID-19 Survivors
JCP
Epilepsy and Suicide Attempt
JCP
Receipt of Antidepressants and Retention in Buprenorphine Treatment for OUD
JCP
Economic Burden of PTSD in the US
PCC
Psychocutaneous Medicine in Iraq
JCP
Transdiagnostic PRS Prediction of Mood Disorders
PCC
Care Management Intervention for Noncardiac Chest Pain
JCP
Co-Occurring Depression and Response During OUD Treatment
JCP
ECT and Death by Suicide
JCP
Effects of a Digital Medicine System on Psychiatric Hospitalization Rates for Adults With Schizophrenia